Tenosynovial Giant Cell Tumor (TGCT) - Market Insights, Epidemiology, and Forecast - 2036 | 7MM Market to Reach USD 3.34 Billion as CSF1R Therapies Drive 20.8% CAGR

The TGCT market is projected to grow from USD 326 million in 2025 to USD 3.34 billion by 2036, driven by a 20.8% CAGR. CSF1R-targeted therapies like pexidartinib (TURALIO) and vimseltinib (ROMVIMZA) are transforming treatment, with emerging candidates including pimicotinib and emactuzumab expected to capture significant market share. The US remains the largest market, with surgery continuing as the primary first-line treatment for localized disease while systemic therapies expand for advanced cases.